Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital

Thirty-day clinical outcomes of the Evolut PRO self-expanding transcatheter aortic valve: the international FORWARD PRO study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review


  1. Contemporary management of severe symptomatic bicuspid aortic valve stenosis: the BiTri Registry

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Threshold for calcium volume evaluation in patients with aortic valve stenosis: correlation with Agatston score

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Spontaneous thrombosis of a transcatheter aortic valve replacement-induced aortic root pseudoaneurysm

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Ganesh Manoharan
  • Eberhard Grube
  • Nicolas M Van Mieghem
  • Stephen Brecker
  • Claudia Fiorina
  • Ran Kornowski
  • Haim Danenberg
  • Hendrik Ruge
  • Holger Thiele
  • Patrizio Lancellotti
  • Lars Søndergaard
  • Corrado Tamburino
  • Jae K Oh
  • Yunhua Fan
  • Stephan Windecker
Vis graf over relationer

AIMS: The Evolut PRO is a new transcatheter heart valve with an outer pericardial wrap intended to reduce paravalvular leak and facilitate tissue ingrowth. We aimed to evaluate the clinical performance and safety of the Evolut PRO valve in standard practice.

METHODS AND RESULTS: FORWARD PRO is a prospective, multinational, multicentre observational study. Transcatheter aortic valve implantation with the Evolut PRO valve (23, 26, or 29 mm) was attempted in 629 non-consecutive patients from 39 centres from February 2018 to January 2019. The primary endpoint was the rate of all-cause mortality at 30 days compared to a pre-specified performance goal. An independent clinical events committee adjudicated safety endpoints based on VARC-2 definitions. All echocardiograms were centrally assessed by an independent core laboratory (Mayo Clinic, Rochester, MN, USA). Baseline characteristics included mean age 81.7±6.1 years, 61.8% female, STS score 4.7±3.3%, and 33.6% were frail. All-cause mortality at 30 days was 3.2%, which was lower than the pre-specified performance goal of 5.5% (p=0.004). Greater than mild AR was present in 1.8% of patients at discharge.

CONCLUSIONS: The FORWARD PRO study confirmed the safety and efficacy of the Evolut PRO transcatheter aortic valve system with an external pericardial wrap. Identifier: NCT03417011 Visual summary. Paravalvular leak at discharge and (right) the Evolut PRO valve (Medtronic) with external pericardial wrap. Reproduced with permission from Medtronic, Inc.

TidsskriftEuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology
Udgave nummer10
Sider (fra-til)850-857
Antal sider8
StatusUdgivet - 20 nov. 2020

ID: 62241392